These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 27145431)

  • 1. Rebiopsy for patients with non-small-cell lung cancer after epidermal growth factor receptor-tyrosine kinase inhibitor failure.
    Kawamura T; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mori K; Nakajima T; Ohde Y; Endo M; Takahashi T
    Cancer Sci; 2016 Jul; 107(7):1001-5. PubMed ID: 27145431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer.
    Kawamura T; Kenmotsu H; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Omae K; Mori K; Tanigawara Y; Nakajima T; Ohde Y; Endo M; Takahashi T
    Clin Lung Cancer; 2018 Mar; 19(2):e247-e252. PubMed ID: 28866043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.
    Koo HJ; Kim MY; Park S; Lee HN; Kim HJ; Lee JC; Kim SW; Lee DH; Choi CM
    Radiology; 2018 Oct; 289(1):227-237. PubMed ID: 30015588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rebiopsy methods and clinical features on T790M mutation after first-line EGFR-TKI treatment failure.
    Zhou J; Li Y; Zhang Y; Dai H; Guo S
    Future Oncol; 2021 Jul; 17(19):2475-2488. PubMed ID: 33769072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.
    Hata A; Katakami N; Yoshioka H; Takeshita J; Tanaka K; Nanjo S; Fujita S; Kaji R; Imai Y; Monden K; Matsumoto T; Nagata K; Otsuka K; Tachikawa R; Tomii K; Kunimasa K; Iwasaku M; Nishiyama A; Ishida T; Nishimura Y
    Cancer; 2013 Dec; 119(24):4325-32. PubMed ID: 24105277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical example.
    Wei B; Zhao C; Li J; Zhao J; Ren P; Yang K; Yan C; Sun R; Ma J; Guo Y
    Mol Oncol; 2019 May; 13(5):1226-1234. PubMed ID: 30927306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Analysis of the Efficacy of Rebiopsy and
    Hong MH; Kim HR; Ahn BC; Heo SJ; Kim JH; Cho BC
    Yonsei Med J; 2019 Jun; 60(6):525-534. PubMed ID: 31124335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer.
    Lin YT; Ho CC; Hsu WH; Liao WY; Yang CY; Yu CJ; Tsai TH; Yang JC; Wu SG; Hsu CL; Hsieh MS; Huang YL; Wu CL; Shih JY
    Cancer Med; 2024 Jan; 13(1):e6870. PubMed ID: 38140788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on prognosis of rebiopsy in advanced non-small cell lung cancer patients after epidermal growth factor receptor-tyrosine kinase inhibitor treatment: a systematic review.
    Imakita T; Matsumoto H; Hirano K; Morisawa T; Sakurai A; Kataoka Y
    BMC Cancer; 2019 Jan; 19(1):105. PubMed ID: 30683066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLC.
    Bosc C; Ferretti GR; Cadranel J; Audigier-Valette C; Besse B; Barlesi F; Decroisette C; Lantuejoul S; Arbib F; Moro-Sibilot D
    Target Oncol; 2015 Jun; 10(2):247-53. PubMed ID: 25119973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M.
    Tseng JS; Su KY; Yang TY; Chen KC; Hsu KH; Chen HY; Tsai CR; Yu SL; Chang GC
    Oncotarget; 2016 Jul; 7(30):48059-48069. PubMed ID: 27384480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
    Kudo K; Nishii K; Makimoto G; Ishikawa N; Tsubata Y; Kodani M; Fujimoto N; Yamasaki M; Kubota T; Takigawa N; Fujitaka K; Kanaji N; Shibayama T; Itano J; Ando C; Hotta K; Kiura K
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1869-1877. PubMed ID: 35386002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations.
    Takeda Y; Naka G; Yamaguchi Y; Hashimoto M; Suzuki M; Izumi S; Sugiyama H
    BMC Cancer; 2020 Oct; 20(1):951. PubMed ID: 33008313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat biopsy of patients with acquired resistance to EGFR TKIs: implications of biopsy-related factors on T790M mutation detection.
    Kim H; Chae KJ; Yoon SH; Kim M; Keam B; Kim TM; Kim DW; Goo JM; Park CM
    Eur Radiol; 2018 Feb; 28(2):861-868. PubMed ID: 28786010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study.
    Nosaki K; Satouchi M; Kurata T; Yoshida T; Okamoto I; Katakami N; Imamura F; Tanaka K; Yamane Y; Yamamoto N; Kato T; Kiura K; Saka H; Yoshioka H; Watanabe K; Mizuno K; Seto T
    Lung Cancer; 2016 Nov; 101():1-8. PubMed ID: 27794396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.